The endometrial biopsy as a guide to the treatment of the luteal phase defect associated with hyperprolactinemia

Barry Israel Witten
In: Fertility and Sterility · 1986 · vol. 46(3) , pp. 397–401 · doi:10.1016/s0015-0282(16)49575-0 · PMID:3743791 · W132314578
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-19 ⓘ

In hyperprolactinemic patients with luteal phase defects, endometrial biopsy-guided therapy combining bromocriptine and clomiphene citrate for glandular stromal asynchrony demonstrated prudent efficacy in managing fertility outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Twenty-five hyperprolactinemic patients were given the diagnosis of associated luteal phase defect (LPD) on the basis of endometrial biopsy. Fifteen patients were found to have glandular stromal synchrony, and 10 had glandular stromal asynchrony (GSA). After 3 months of initial bromocriptine therapy, the patients were divided into two groups and treated separately on the basis of the endometrial histologic pattern found. Persistent GSA was complemented with clomiphene citrate. The raw pregnancy rates were identical for both groups. Progesterone values between the two groups were not significantly different. Life-table analysis projected the cumulative pregnancy rate on the basis of the protocol of therapy administered. The efficacy of utilizing a combined drug approach based on the endometrial biopsy seems prudent in managing the fertility rate of the hyperprolactenemic patient with LPD.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (21)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-09-09T06:31:01.691765+00:00
License: CC0 · commercial use OK